M
MannKind Corp D
D
MNKD
2.76500
USD
-0.02
(-0.54%)
مغلق
حجم التداول
211,806
الربح لكل سهم
0
العائد الربحي
-
P/E
140
حجم السوق
849,049,327
المقالات
العنوان: MannKind Corp
القطاع: Healthcare
الصناعة: Biotechnology
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Companyis currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.